Navigation Links
Many Dialysis Patients Get Wrong Blood Thinners for Angioplasty

Some docs not following FDA directive urging against use of Lovenox, Integrilin, study shows

TUESDAY, Dec. 8 (HealthDay News) -- More than one-fifth of patients on dialysis who undergo angioplasty are given blood thinners they should not be given, new research shows.

As a result, these patients are subject to a higher rate of bleeding during their hospital stay and may even be at a higher risk of dying, according to a report in the Dec. 9 issue of the Journal of the American Medical Association.

The drugs in question are enoxaparin (Lovenox), a low-molecular-weight heparin, and eptifibatide (Integrilin). The U.S. Food and Drug Administration (FDA) has determined that neither medication should be used in people undergoing dialysis.

"The study does validate the FDA's directed labeling [of these drugs] as contraindicated, and it supports avoiding use of these drugs in dialysis patients," said study author Dr. Thomas Tsai, director of interventional cardiology at the Denver VA Medical Center and an assistant professor of cardiology at the University of Colorado Denver.

"I was surprised by this," said Dr. Gregory Dehmer, a professor of internal medicine at Texas A&M Health Science Center and director of the cardiology division at Scott & White in Temple, Texas. "Clearly this indicates there's a tremendous opportunity for improvement on the part of interventional cardiologists."

According to Tsai, this particular type of medicating error may stem from the simple fact that there are so many possible medications for physicians to choose from now.

"Clearly, there's an explosion of different medications out there," he said. "I did some calculations, and found 60 combinations of medication alone that we're faced with using in the cath lab for these patients. If you take into consideration the order in which they're administered, there are over 1,000 permutations."

Ease of use and convenience may also play a role in doctors' turning to these particular drugs, Tsai said.

Meanwhile, the population of people undergoing dialysis is also exploding, and is projected to pass the 2 million mark worldwide by 2010, according to the study.

Angioplasty, also known as percutaneous coronary intervention (PCI), involves widening a blood vessel to ease the flow of blood in patients with narrowed arteries.

For this study, data on 22,778 dialysis patients who had undergone PCI between 2004 and 2008 revealed that 22.3 percent received a blood thinner they should not have been getting. Almost half received enoxaparin and almost two-thirds eptifibatide. About 11 percent received both.

Those patients who did receive a contraindicated drug had a 66 percent higher risk of in-hospital bleeding, and there was some indication that mortality risk might have been elevated as well.

"There was a signal towards increased in-hospital mortality ... so there is a possible trend," Tsai said, adding that this linkage was not yet certain.

Such errors could be introduced at any step in the continuum of care, from the emergency room to the cath lab and anywhere in between, Dehmer said.

"This reflects poorly on the entire process of care, which may start at the outlying hospital or may start in the cath lab," he said. "This represents a very strong call to action on the part of all those who are involved with the care of patients who ultimately wind up having PCI."

Health-care providers do have access to alternative blood thinners when treating this group of patients.

And these contraindicated drugs might even work in hemodialysis patients at the right doses, it's just that no one has ever looked at this, explained Dr. William O'Neill, executive dean for clinical affairs at the University of Miami Miller School of Medicine.

"Poor kidney function almost always disqualifies patients from clinical trials," he explained. "Do the drugs get filtered out [of the bloodstream by the kidneys]? Basically nobody knows because nobody has done the trials. There is just an absolute glaring lack of information about how to use these drugs in these patients. This study does suggest a fundamental lack of understanding of these drugs among a significant minority of physicians."

More information

The American Heart Association has more on percutaneous coronary intervention.

SOURCES: Thomas T. Tsai, M.D., director, interventional cardiology, Denver VA Medical Center, and assistant professor, cardiology, University of Colorado Denver School of Medicine; Gregory Dehmer, M.D., professor, internal medicine, Texas A&M Health Science Center, and director, cardiology division, Scott & White, Temple, Texas; William O'Neill, M.D., executive dean, clinical affairs, University of Miami Miller School of Medicine; Dec. 9, 2009, Journal of the American Medical Association

Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Clinical trials present better alternatives for dialysis patients
2. Nighttime Home Dialysis a Boon for Kidney Patients
3. Nations Largest Dialysis Patient Organization Recognizes the Achievements of Patients and Leaders in Kidney Care
4. WellBound Teams With Kaiser Permanente to Open New Self-Care Dialysis Center in Sacramento, CA
5. New peritoneal dialysis diagnostic discovered
6. Early intervention dramatically improves outcomes for new dialysis patients
7. Dialysis Corporation of America Announces Third Quarter 2007 Earnings Release Date
8. Renal Solutions, Inc. Announces FDA 510(k) Clearance of New Design of the Allient(R) Sorbent Hemodialysis System for Chronic and Acute Hemodialysis
9. DaVita Emergency Response Efforts Ensure Vital Treatment for More than 700 Kidney Failure Patients in Need of Life-Saving Dialysis Treatments in Areas Affected by Southern California Wildfires
10. DaVita to Open First Independent Dialysis Clinic in Fargo-Moorhead
11. Home Dialysis Clinical Research Study is Underway - Focuses on At-Home Extended Duration Treatment
Post Your Comments:
(Date:11/24/2015)... Peoria, IL (PRWEB) , ... November 24, 2015 , ... Dr. Rodney E. Willey ... His new venture, Koala Center for Sleep Disorders, provides treatment for snoring and ... dentists who have opened a Koala Center for Sleep Disorders in the US, one of ...
(Date:11/24/2015)... ... November 24, 2015 , ... Bibliomotion is thrilled to ... Me about Reinvention and Diversity by Nancy M. Schlichting, Chief Executive Officer ... failing to adequately address the needs of patients and their families, shaped my desire ...
(Date:11/24/2015)... ... November 24, 2015 , ... World Patent ... Blending, a household invention that revolutionizes the vending machine industry by providing healthy ... is worth $2 billion," says Scott Cooper, CEO and Creative Director of World ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... announces Fragrance by Marcelle, a cosmetic invention which offers a combination of natural ... Market in the US is worth $3 billion annually," says Scott Cooper, CEO ...
(Date:11/24/2015)... ... , ... “I am so thrilled, as a newbie here, to leave a mark for the ... School Lounge Makeover® from California Casualty . Stephanie is in her fifth year teaching ... longer tenure. , “This is such an amazing school and we deserve a space where ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 2015 Sectra (STO: SECT B) ... into a multi-year agreement to deploy Breast Imaging ... provide the Breast Center a future-proof platform capable of ... SECT B) announces that Breast Center of Acadiana ... Breast Imaging PACS in its two freestanding imaging centers. This ...
(Date:11/24/2015)... 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ASDS ... of Directors has declared a special 1 percent stock dividend ... payable December 14, 2015, to shareholders of record December 7, ... additional shares of common stock. --> ... a strong endorsement of our confidence in Ascendant,s growth strategy ...
(Date:11/24/2015)... 2015 iRhythm Technologies, Inc. , a leading digital ... that it will participate in the 27th Annual Piper Jaffray Healthcare ... York, NY . Kevin King , Chief Executive ... 2015 at 8:50am ET. --> ... --> . --> iRhythm is a ...
Breaking Medicine Technology: